Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ruxolitinib Phosphate

FDA-approved product (tablet, oral), marketed as Leqselvi, Jakafi, Jakafi Xr and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ruxolitinib Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alopecia areata
  • Cancer
  • Eczematoid dermatitis
  • Graft versus host disease
  • Myelofibrosis
  • Myeloproliferative disorder
  • Neoplasm
  • Polycythemia vera
  • Primary myelofibrosis
  • Vitiligo

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids; Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor; Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ruxolitinib Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ruxolitinib Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

    NCT07498205 · start 2026-11

    Registered record
    Registry ID
    NCT07498205
    Conditions
    Myelofibrosis; Myelofibrosis (MF)
    Interventions
    Momelotinib; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2031-08-08
    Enrolment
    268

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis; Myelofibrosis (MF)
    InterventionMomelotinib; Ruxolitinib
    PhasePhase 4
    Registry statusNot yet recruiting

  • Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

    NCT07801248 · start 2026-10-01

    Registered record
    Registry ID
    NCT07801248
    Conditions
    Acute Skin Graft Versus Host Disease (GVHD)
    Interventions
    Ruxolitinib 1.5% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Skin Graft Versus Host Disease (GVHD)
    InterventionRuxolitinib 1.5% cream
    PhasePhase 1
    Registry statusNot yet recruiting

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    NCT07352566 · start 2026-08-01

    Registered record
    Registry ID
    NCT07352566
    Conditions
    Psoriasis; Atopic Dermatitis
    Interventions
    In situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene; Tapinarof; Crisaborole; Tacrolimus; Adalimumab; Etanercept; Certolizumab; Infliximab; Secukinumab; Ixekizumab; Apremilast; Risankizumab; Ustekinumab; Hydroxychloroquine; Methotrexate; Mycophenolate; Azathioprine; Chloroquine; Cyclosporine; Tofacitinib; Deucravacitinib; Dupilumab; Tralokinumab; Guselkumab; Tildrakizumab; Baractinib; Abrocitinib; Upadacitinib; Lebrikizumab; Nemolizumab; Ruxolitinib; Bimekizumab; Roflumilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis
    InterventionIn situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene +32 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

    NCT07252050 · start 2026-06-08

    Registered record
    Registry ID
    NCT07252050
    Conditions
    Sickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation; Graft Failure
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-06-08
    Completion
    2029-11-19
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation +1 more
    InterventionRuxolitinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

    NCT07464951 · start 2026-05-14

    Registered record
    Registry ID
    NCT07464951
    Conditions
    Acute Myeloid Leukemia (AML)
    Interventions
    Anti-CD123 LV redirected T cells (CART123); Ruxolitinib (JAKAVI®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-14
    Completion
    2030-05-14
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML)
    InterventionAnti-CD123 LV redirected T cells (CART123); Ruxolitinib (JAKAVI®)
    PhasePhase 1
    Registry statusRecruiting

  • A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

    NCT07317700 · start 2026-02-13

    Registered record
    Registry ID
    NCT07317700
    Conditions
    MF
    Interventions
    Flonoltinib 75mg; Ruxolitinib Phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-02-13
    Completion
    2028-03-30
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMF
    InterventionFlonoltinib 75mg; Ruxolitinib Phosphate
    PhasePhase 3
    Registry statusRecruiting

  • Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

    NCT07085039 · start 2025-12-18

    Registered record
    Registry ID
    NCT07085039
    Conditions
    Castleman's Disease (CD); Idiopathic Multicentric Castleman' s Disease
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-18
    Completion
    2028-12-31
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastleman's Disease (CD); Idiopathic Multicentric Castleman' s Disease
    InterventionRuxolitinib
    PhasePhase 2
    Registry statusRecruiting

  • Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

    NCT06991101 · start 2025-12-03

    Registered record
    Registry ID
    NCT06991101
    Conditions
    Glioblastoma; Brain Cancer; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult; MGMT-Unmethylated Glioblastoma; MGMT-Methylated Glioblastoma
    Interventions
    Ruxolitinib; Temozolomide; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-03
    Completion
    2030-12
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Brain Cancer; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain +3 more
    InterventionRuxolitinib; Temozolomide; Radiation Therapy
    PhasePhase 2
    Registry statusRecruiting

  • Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

    NCT07366801 · start 2025-09-03

    Registered record
    Registry ID
    NCT07366801
    Conditions
    Acute Myeloid Leukemia, Relapsed; Acute Lymphoblastic Leukemia, High Risk; Acute Myeloid Leukemia, High Risk; Acute Lymphoblastic Leukemia, Relapse
    Interventions
    Cyclosporine A (CsA); Sirolimus; Ruxolitinib (JAKAVI®); Abatacept
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-09-03
    Completion
    2028-02-03
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia, Relapsed; Acute Lymphoblastic Leukemia, High Risk; Acute Myeloid Leukemia, High Risk; Acute Lymphoblastic Leukemia, Relapse
    InterventionCyclosporine A (CsA); Sirolimus; Ruxolitinib (JAKAVI®); Abatacept
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

    NCT06548360 · start 2025-01-24

    Registered record
    Registry ID
    NCT06548360
    Conditions
    NonSegmental Vitiligo
    Interventions
    Ruxolitinib Cream; Vehicle Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-24
    Completion
    2028-12-20
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonSegmental Vitiligo
    InterventionRuxolitinib Cream; Vehicle Cream
    PhasePhase 3
    Registry statusRecruiting

  • BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

    NCT06477549 · start 2024-06-21

    Registered record
    Registry ID
    NCT06477549
    Conditions
    Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myeloproliferative Neoplasm; Myelodysplastic Syndromes
    Interventions
    Bendamustine Hydrochloride; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-21
    Completion
    2029-06
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma +2 more
    InterventionBendamustine Hydrochloride; Ruxolitinib
    PhasePhase 2
    Registry statusRecruiting

  • Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

    NCT06261021 · start 2024-04-19

    Registered record
    Registry ID
    NCT06261021
    Conditions
    Discoid Lupus Erythematosus
    Interventions
    Ruxolitinib 1.5% cream; Application without occlusion in Area 1; Application under occlusion at night in Area 2; Application under occlusion at night in Area 1; Application without occlusion in Area 2
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-19
    Completion
    2026-02-28
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiscoid Lupus Erythematosus
    InterventionRuxolitinib 1.5% cream; Application without occlusion in Area 1; Application under occlusion at night in Area 2; Application under occlusion at night in Area 1 +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas

    NCT05872477 · start 2023-09-05

    Registered record
    Registry ID
    NCT05872477
    Conditions
    Vitiligo
    Interventions
    Ruxolitinib Topical; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-09-05
    Completion
    2025-01-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionRuxolitinib Topical; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

    NCT06209606 · start 2022-12-08

    Registered record
    Registry ID
    NCT06209606
    Conditions
    Multiple Myeloma
    Interventions
    Ruxolitinib Oral Tablet [Jakafi]; Lenalidomide; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2022-12-08
    Completion
    2029-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionRuxolitinib Oral Tablet [Jakafi]; Lenalidomide; Methylprednisolone
    PhaseEarly phase 1
    Registry statusRecruiting

  • Ruxolitinib in Seborrheic Dermatitis

    NCT05787860 · start 2022-11-15

    Registered record
    Registry ID
    NCT05787860
    Conditions
    Seborrheic Dermatitis
    Interventions
    Ruxolitinib 1.5% Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-11-15
    Completion
    2024-01-26
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeborrheic Dermatitis
    InterventionRuxolitinib 1.5% Cream
    PhasePhase 2
    Registry statusCompleted